Maham Fatima
Tue, January 27, 2026 astatine 7:38 AM CST 1 min read
On January 9, Bernstein adjusted its outlook for DexCom, expanding the terms people to $86 from $84 portion maintaining an Outperform rating. This update came arsenic US healthcare stocks showed signs of betterment pursuing a important debased constituent successful September 2025. The steadfast noted that arsenic the macroeconomic and argumentation uncertainties that hampered the assemblage passim 2025 statesman to clear, healthcare equities are well-positioned for a stronger show successful 2026.
jason-briscoe-Gw_sFen8VhU-unsplash
Furthermore, connected January 7, RBC Capital expert Shagun Singh Chadha maintained a Buy standing connected DexCom Inc. (NASDAQ:DXCM) portion mounting a terms people of $85.
DexCom Inc. (NASDAQ:DXCM) is simply a aesculapian instrumentality institution that focuses connected the design, development, and commercialization of CGM (continuous glucose monitoring) systems successful the US and internationally.
While we admit the imaginable of DXCM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 week ago
7





English (CA) ·
English (US) ·
Spanish (MX) ·